Analyst Coverage

The following research analysts cover Destiny Pharma.

Mark Brewer, finnCap	+44(0)20 7220 0500
Andy Smith, Equity Development	+44(0)20 7065 2690
Karl Keegan, Singer Capital Markets	+44(0)20 7496 3187

Please click on links below to access coverage published:

	finnCap Analyst research from finnCap can be obtained by registering on the link above 12 April 2022 – Full-year results – looking to partnering deals 9 March 2022 – Placing raises £6m with Open Offer up to £1m
	Equity Development 12 April 2022 – Results bring welcome detail and no surprises 29 March 2022 – NTCD-M3 competitors stumble while issue approved
	Proactive Investors For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above
	VOX Markets For further commentary and interviews, please visit the Destiny Pharma page at Vox Markets on the link above